Clinical Trial Update: AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AMG 102 in combination with pemetrexed disodium and cisplatin for malignant pleural mesothelioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Mesothelioma
• Malignant Mesothelioma
• Malignant Pleural Mesothelioma
• Sarcomatous Mesothelioma

Drugs mentioned

• AMG 102 (AMG 102)
• CISPLATIN (cisplatin)
• Pemetrexed disodium (Pemetrexed disodium)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Status: WITHDRAWN